Escutia-Cuevas HH, Fernández-Ceseña E, Alcántara-Meléndez MA, Figueroa-Cabrera A, López-Rosas R, Campuzano-Pineda L

Language: English
References: 11
Page: 166-170
PDF size: 382.96 Kb.

ABSTRACT

Introduction: A case report describing the use of bio-absorbable vascular scaffolds in a patient with rare anomalous origin of right coronary artery. Case report: Male 71 years, ST-segment elevation myocardial infarction in the inferior region wall, thrombolysis with tenecteplase, with reperfusion criteria. Coronary angiography: left coronary system without angiographic lesions, right coronary artery with a significant lesion in the middle segment. An elective percutaneous coronary intervention was performed using 2 bio-absorbable vascular scaffolds (Absorb 3.5 x 28 mm joined in proximal segment with an Absorb 3.5 x 23 mm), posterior review with optical coherence tomography. Results: Discharged 24 hours later, remaining asymptomatic at 6 months follow-up. Conclusion: In this case, the significant stenosis of the artery involved was treated with the implantation of two bio-absorbable vascular scaffolds, obtaining an appropriate outcome after six months follow-up. This is the first report of a patient with anomalous origin of the right coronary artery treated with bio-absorbable vascular scaffolds in Mexico.

REFERENCES

1. Villa A, Sammut E, Nair A, Rajani R, Bonamini R, Chiribiri A. Coronary artery anomalies overview: the normal and the abnormal. World J Radiol. 2016; 8 (6): 537-555.

2. Narayanan SR, Al Shamkhani W, Rajappan AK. Anomalous origin of RCA from left coronary sinus presenting as PSVT and recurrent acute coronary syndromes. Indian Heart J. 2016; 68: 208-210.

3. Angelini P. Coronary artery anomalies: an entity in search of an identity. Circulation. 2007; 115 (10): 1296-1305.

4. Ormiston J, Serruys P. Contemporary reviews in interventional cardiology: bioabsorbable coronary stents. Circ Cardiovasc Interv. 2009; 2: 255-260.

5. Lane J, Perkins L, Sheehy A. Lumen gain and restoration of pulsatility after implantation of a bioresorbable vascular scaffold in porcine coronary arteries. JACC Cardiovasc Interv. 2014; 7: 688-695.

6. Diletti R, Serruys P, Farooq V. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J. 2012; 164 (5): 654-663.

7. Ellis S, Kereiakes D, Metzger C. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015; 373: 1905-1915.

8. Puricel S, Arroyo D, Corpataux N. Comparison of everolimus and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol. 2015; 65: 791-801.

9. Capodanno D, Gori T, Nef H. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015; 10: 1144-1153.

10. Serruys P, Chevalier B, Dudek D. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015; 385: 43-54.

11. Yew K. Guidezilla guide extension catheter enhances the delivery of bioresorbable vascular scaffold in an anomalous coronary artery. Int J Cardiol. 2016; 223: 239-241.